
Omnicell, Inc. (NASDAQ:OMCL – Free Report) – Research analysts at Zacks Research increased their FY2026 EPS estimates for Omnicell in a report issued on Tuesday, November 17th. Zacks Research analyst Team now anticipates that the company will earn $1.73 per share for the year, up from their prior estimate of $1.49. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.76 per share. Zacks Research also issued estimates for Omnicell’s Q4 2026 earnings at $0.23 EPS, Q1 2027 earnings at $0.24 EPS, Q2 2027 earnings at $0.24 EPS, Q3 2027 earnings at $0.29 EPS, Q4 2027 earnings at $0.40 EPS, FY2027 earnings at $1.17 EPS, Q1 2028 earnings at $0.31 EPS, Q2 2028 earnings at $0.32 EPS, Q3 2028 earnings at $0.33 EPS and FY2028 earnings at $1.33 EPS.
Omnicell (NASDAQ:OMCL – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.16. The company had revenue of $307.85 million for the quarter, compared to analyst estimates of $304.44 million. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The firm’s revenue was down .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.51 EPS.
Get Our Latest Analysis on Omnicell
Omnicell Stock Performance
NASDAQ OMCL opened at $32.51 on Thursday. The firm’s fifty day moving average price is $35.12 and its two-hundred day moving average price is $38.06. The stock has a market cap of $1.50 billion, a PE ratio of 22.43, a PEG ratio of 0.88 and a beta of 0.88. Omnicell has a fifty-two week low of $31.75 and a fifty-two week high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.45 and a current ratio of 1.65.
Institutional Investors Weigh In On Omnicell
A number of institutional investors have recently added to or reduced their stakes in OMCL. BlackRock Inc. bought a new stake in Omnicell in the second quarter valued at approximately $313,044,000. Dimensional Fund Advisors LP raised its holdings in Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after purchasing an additional 137,834 shares during the last quarter. American Century Companies Inc. raised its holdings in Omnicell by 796.8% during the 3rd quarter. American Century Companies Inc. now owns 972,984 shares of the company’s stock worth $33,130,000 after purchasing an additional 864,492 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Omnicell by 15.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 625,671 shares of the company’s stock worth $21,304,000 after purchasing an additional 85,236 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Omnicell by 31.3% during the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock worth $19,390,000 after purchasing an additional 138,537 shares during the last quarter. 97.70% of the stock is owned by institutional investors.
Trending Headlines about Omnicell
These are some of the OMCL headlines that stood out recently:
- Positive Sentiment: Zacks raised its FY2026 EPS estimate to $1.73 from $1.49 and highlighted Titan XT, OmniSphere, recurring revenue and cost discipline as parts of Omnicell’s growth and profitability strategy. Article: Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
- Positive Sentiment: A Zacks article characterized OMCL as a strong value stock, which may appeal to investors seeking comparatively attractive valuations. Article: Here's Why Omnicell Is a Strong Value Stock
- Neutral Sentiment: A Seeking Alpha analysis presents Omnicell’s net-cash balance sheet as a potential competitive tool against Pyxis, though the provided entry does not include details of the argument. Article: Omnicell: Turning a Net Cash Balance Sheet Into a Weapon Against Pyxis
About Omnicell
Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.
Recommended Stories
- Five stocks we like better than Omnicell
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
